RH Nanopharmaceuticals is a Physicians' owned pharmaceutical research and development company dedicated to treating, preventing, slowing and reversing current acute and chronic inflammatory diseases such as Osteoarthritis, Hemophilic Arthritis, Type 2 Diabetes, Acute and Chronic Pain including postoperative Pain, Sickle cell vaso occlusive crisis related pain, Traumatic Brain Injury(TBI), Alzheimer’s Disease, Anterior Uveitis, and Neuropathic Corneal Pain (NCP), to name but a few. Our leading assets are RHN-001, RHN- 002, and RHN-003.
RH Nanopharmaceuticals was founded in 2017 to address the unmet need for a safer and effective analgesic/anti inflammatory for pain and inflammation. Both Dr Ross and Dr Hasan have treated thousands of patients with the current pain medications including the NSAIDs as well as the opioids and felt strongly that drug repurposing and innovative formulation strategies can address this highly desirable unmet need of a safer analgesic. Over a short period of 3 years, RH Nanopharma has achieved various milestones of developing multiple dosage formulations for several indications including arthritis, acute postoperative pain, and a few orphan diseases. We are a clinical stage company with a Phase 1 trial in progress and other formulations in pre clinical stage.